Daiichi Sankyo - DSNKY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$27.90
▲ +0.2 (0.72%)

This chart shows the closing price for DSNKY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daiichi Sankyo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSNKY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSNKY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Daiichi Sankyo in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $27.90.

This chart shows the closing price for DSNKY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Daiichi Sankyo.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2022Jefferies Financial GroupUpgradeHold ➝ Buy
3/8/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
6/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
12/9/2019Jefferies Financial GroupInitiated CoverageBuy
2/21/2018CitigroupDowngradeNeutral ➝ Sell
(Data available from 9/26/2017 forward)

News Sentiment Rating

-0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/28/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
4/29/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/29/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 6 very negative mentions
6/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
7/28/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
8/27/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
9/26/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Daiichi Sankyo logo
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $27.90
Low: $27.50
High: $28.00

50 Day Range

MA: $28.41
Low: $24.35
High: $31.83

52 Week Range

Now: $27.90
Low: $19.39
High: $32.35

Volume

51,849 shs

Average Volume

121,543 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Daiichi Sankyo?

The following Wall Street analysts have issued research reports on Daiichi Sankyo in the last year: Jefferies Financial Group Inc..
View the latest analyst ratings for DSNKY.

What is the current price target for Daiichi Sankyo?

0 Wall Street analysts have set twelve-month price targets for Daiichi Sankyo in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Daiichi Sankyo in the next year.
View the latest price targets for DSNKY.

What is the current consensus analyst rating for Daiichi Sankyo?

Daiichi Sankyo currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DSNKY will outperform the market and that investors should add to their positions of Daiichi Sankyo.
View the latest ratings for DSNKY.

What other companies compete with Daiichi Sankyo?

How do I contact Daiichi Sankyo's investor relations team?

Daiichi Sankyo's physical mailing address is Daiichi Sankyo Bldg. A/B Kan, Chuo Ku, Tokyo To 103-8426. The company's listed phone number is (136) 225-1111. The official website for Daiichi Sankyo is www.daiichisankyo.com. Learn More about contacing Daiichi Sankyo investor relations.